Shire (LON:SHP)‘s stock had its “buy” rating reaffirmed by research analysts at Deutsche Bank in a report released on Thursday. They presently have a GBX 5,000 ($67.81) target price on the biopharmaceutical company’s stock. Deutsche Bank’s price target would suggest a potential upside of 36.76% from the company’s previous close.

SHP has been the subject of a number of other research reports. Goldman Sachs Group reissued a “conviction-buy” rating on shares of Shire in a research note on Tuesday, October 17th. Shore Capital reaffirmed a “buy” rating on shares of Shire in a research report on Monday, November 13th. Liberum Capital lowered their price target on Shire from GBX 4,400 ($59.67) to GBX 4,200 ($56.96) and set a “hold” rating for the company in a research report on Tuesday, October 24th. Morgan Stanley lowered their price target on Shire from GBX 5,800 ($78.65) to GBX 5,700 ($77.30) and set an “overweight” rating for the company in a research report on Thursday, October 12th. Finally, HSBC lowered their price target on Shire from GBX 4,050 ($54.92) to GBX 3,800 ($51.53) and set a “hold” rating for the company in a research report on Tuesday, November 21st. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of GBX 5,152.94 ($69.88).

Shares of Shire (LON SHP) opened at GBX 3,656 ($49.58) on Thursday. Shire has a 52 week low of GBX 3,435.50 ($46.59) and a 52 week high of GBX 5,067 ($68.71). The firm has a market capitalization of $33,350.00 and a PE ratio of 2,790.84.

In other news, insider Dominic Blakemore bought 165 shares of Shire stock in a transaction on Tuesday, December 19th. The shares were purchased at an average price of GBX 3,790 ($51.40) per share, for a total transaction of £6,253.50 ($8,480.47).

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/shire-shp-given-buy-rating-at-deutsche-bank/1802337.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with Analyst Ratings Network's FREE daily email newsletter.